Evotec and Research Support International Form Joint Venture Evotec-RSIL Ltd
News Jul 11, 2007
Evotec AG and Research Support International Limited (RSIL), a subsidiary of DIL Ltd, have announced the formation of a joint venture in India, Evotec-RSIL Ltd, to design, synthesise and manage compound libraries as a service.
The joint venture will combine Evotec’s expertise in library design, synthesis, analysis, purification and project management with RSIL’s first class scientists coupled with a low cost structure in India to provide a high quality, cost efficient solution for the provision and management of compound libraries to the pharmaceutical industry.
The joint venture will be located in Thane, India, and will use newly constructed laboratories. Evotec will contribute its proprietary technologies, years of experience and expertise in library synthesis in addition to providing a range of parallel synthesis equipment, high throughput analytical apparatus and expert training in the design, synthesis and management of compound libraries.
Evotec-RSIL Ltd will design compound libraries of low hundreds to thousands of compounds per scaffold by accessing chemistries already validated at Evotec and/or RSIL. As well as being able to design and synthesise compound libraries the joint venture will also offer library management services in which it will be able to analyse and purify large screening libraries in a cost efficient manner.
“Evotec has enjoyed an enviable reputation in the synthesis of large screening and focused libraries for many years. Through this joint venture we are able to team up with the excellent scientists and management at RSIL to continue to provide this invaluable service at competitive prices for our customers. We are very pleased to collaborate with RSIL, one of India’s premier chemistry services business“, commented Dr Mario Polywka, Chief Operating Officer of Evotec.
“With the formation of this joint venture through a contribution in kind of Evotec’s library business, Evotec is making another significant step in its strategy to focus its core business in Europe on high value solutions and products for the pharmaceutical industry,” Polywka continued.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE